logo-loader

US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer

Last updated: 08:52 19 Apr 2018 BST, First published: 13:52 19 Apr 2018 BST

lungs
Lung cancer is the leading cause of cancer death among men and women

AstraZeneca PLC’s (LON:AZN) lung cancer drug, Tagrisso, has been approved by the US Food and Drug Administration as a first-line treatment.

The approval is for patients whose tumours have certain mutations have epidermal growth factor receptor (EGFR) mutations.

Tagrisso has been used as a second-line treatment in the US since last March, while the pill is still under regulatory review in the EU and Japan for use in the first-line treatment setting, with decisions expected later this year.

“Today's FDA approval of Tagrisso in the 1st-line setting is an exciting milestone for patients and our company,” Astra’s head of oncology Dave Fredrickson.

“Tagrisso delivered unprecedented median progression-free survival data across all pre-specified patient subgroups, including patients with or without CNS metastases, and could prolong the lives of more patients without their tumours growing or spreading.”

AstraZeneca shares edged 6p higher to £49.70 in early deals on Thursday.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

19 minutes ago